Image source: Shutterstock

Highlights

  • Verve Therapeutics (VERV) stock surged 24.5% Tuesday, with intraday gains peaking at 41%.

  • The rally follows positive Phase 1b trial data for its cholesterol-lowering gene-editing treatment, VERVE-102.

  • Multiple analysts upgraded the stock and raised price targets, citing stronger-than-expected efficacy and safety.

  • Cantor Fitzgerald upgraded to "Overweight", Guggenheim sees a 75% probability of success, and Canaccord lifted its target to $39/share.

Verve Therapeutics (NASDAQ:VERV) exploded higher Tuesday after releasing encouraging early-stage clinical data for its experimental gene-editing treatment VERVE-102, aimed at treating heterozygous familial hypercholesterolemia (HeFH) and premature coronary artery disease.

The Heart-2 Phase 1b trial results, published Monday, exceeded expectations on both efficacy and safety, fueling investor optimism and sparking a wave of analyst upgrades.

Among the most bullish calls:

  • Cantor Fitzgerald upgraded Verve from neutral to overweight, noting the treatment's safety profile and impact on LDL cholesterol levels.

  • Guggenheim maintained its buy rating but raised its price target from $18 to $24, increasing its probability of regulatory success to 75%, up from 60%.

  • Canaccord gave the most enthusiastic nod, boosting its price target from $32 to $39, calling the trial results a “knockout” in terms of both safety and efficacy.

VERVE-102 is part of Verve’s broader pipeline of in vivo gene editing therapies, designed to offer one-time treatments for cardiovascular diseases by permanently turning off the PCSK9 gene—a well-known driver of cholesterol levels.